glp 1 cardiac benefit The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action The Cardiovascular Physiology of Glucagon-like

Because when care adapts to your life, your progress lasts

Key Toxicities to Watch as a clinical pharmacist: Renal: nephrotoxicity, rising creatinine Neuro: tremors,confusion, seizures Metabolic: hypertension, QT prolongation, hyperglycemia Electrolytes: K, Mg Heres how we intervene before toxicity takes over: Slash Tacrolimus doses by ~70% when starting Posaconazole TDM every 23 days (dont wait for trouble) Monitor renal function, BP, electrolytes, glucose closely Anticipate the reverse interaction when Posaconazole is stopped tacrolimus levels crash without timely adjustment Key Insight: Pharmacists arent just dose adjusters. We are the safety net that spots silent drugdrug collisions before they harm patients

AI will also play a commercial role in helping engage payers by demonstrating that certain therapeutic outcomes can help prevent type 2 diabetes, reduce cardiovascular risks, and save on overall health costs

These appointments allow for medication optimisation, complication screening, and discussion of treatment goals

NAION and GLP-1 RAs Recent studies have indicated a possible link between GLP-1 receptor agonists semaglutide and liraglutide and an increased risk of NAION, or non-arteritic anterior ischemic optic neuropathy

GLP-based treatments may support healthier metabolic function, improved insulin sensitivity, reduced inflammation, digestive health, and long-term wellness goals